Anumana named in Fierce Medtech's Fierce 15 for 2022

Anumana, Inc.™ is a health technology company from nference and Mayo Clinic Platform, harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early.

About Us

Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum. Anumana is on a mission to unlock the electrical signals of the heart to power earlier and improved diagnosis, treatment, and interventions in cardiology.

Anumana’s AI solutions are investigational medical devices and have not yet received regulatory approval or clearance. For more information, follow Anumana on LinkedIn and Twitter.

Murali Aravamudan is a serial entrepreneur, inventor and engineer who has built, led and exited several successful media and telecom technology companies. He is the co-founder of nference and CEO of Anumana.

In 2005, Mr. Aravamudan co-founded and served as chief executive officer of Veveo, a software company that enabled quick, efficient content discovery in input-constrained devices, including televisions and mobile phones. As CEO of Veveo, he established the company’s leadership in its target market segments with more than 100 million device deployments, as well as its innovation of conversational interfaces. His leadership translated into an expanding patent portfolio for Veveo with 95 granted US patents and 70+ pending applications. He helped raise $28M in equity in two rounds from Matrix Partners, Norwest Ventures and Northbridge Ventures. Veveo was acquired by TiVo (formerly Rovi) in 2014 for over $75M.

Mr. Aravamudan founded Winphoria Networks in 2000 and served as chief technology officer until its acquisition by Motorola in 2003 for $200M. Mr. Aravamudan then served as vice president and general manager of the Winphoria division of Motorola’s Global Telecom Solutions Sector. Winphoria pioneered development of the mobile wireless softswitch and instant communications applications for mobile networks. At Winphoria he helped raise $54M in equity in two rounds from Matrix Partners, Norwest Ventures and Northbridge Ventures.

Earlier in his career, Mr. Aravamudan served as vice president and chief technology officer of the communications software business at Lucent Technologies and as department head of communications software research at Bell Laboratories. He was a principal involved in the creation of softswitch, the revolutionary technology for IP-based telephone networks that is today the foundation for next-generation converged voice and data networks.

Mr. Aravamudan has authored 115 US patents and has more than 100 patents pending in the areas of search, personalization, conversational interfaces, machine learning/AI systems, data networking, telephony and, recently, computational biology. He holds a master’s degree in Electrical Communication Engineering from the Indian Institute of Science.

David McMullin has more than two decades of experience in corporate development, strategic planning, commercialization and operations across multiple sectors in the life sciences industry. In addition to serving as chief business officer of Anumana, he continues in his role of chief strategy officer of nference.

Prior to joining nference and Anumana, Mr. McMullin served as chief business officer of Aldeyra Therapeutics, a Nasdaq listed biotechnology company. Before Aldeyra, Mr. McMullin ran U.S. Internal Medicine at Shire plc, a $1.4 billion rare disease and specialty pharmaceutical company, and was previously the head of Global Commercial Operations at Shire. Prior to his work at Shire, he was the vice president of Global Supply Chain Management and Strategy at Novartis. He holds an MBA with high distinction as a Baker Scholar from Harvard University and a bachelor’s degree in Economics from Brigham Young University.

Hutch Fishman has more than two decades of experience as a founding CFO of successful startups in technology, healthcare, ecommerce, communications and networking. He has been the CFO of Anumana since its founding.    

Previously, Mr. Fishman has been the founding CFO of nference, Affirmed Networks, recently acquired by Microsoft; Veveo, acquired by TiVo; Sonus Networks which went public and Motorola-acquired Winphoria Networks. He also served as CFO for Viaweb, acquired by Yahoo!, which was founded by Paul Graham of Y Combinator. He was previously a senior manager at Deloitte & Touche. He holds a B.S. in Accounting from Bryant University.

Anand Ramani joined as SVP of Engineering as part of the Neutrace acquisition.Prior to joining Anumana, Anand was leading the product engineering for Neutrace which had a suite of data driven AI products in the Electrophysiology space.

Prior to Neutrace, Anand was the CTO at AmberTAG Inc a social venture working on multiple ventures. As an early employee of Yahoo, Anand led the Yahoo Image, Video and Audio Search team. Anand was instrumental in growing the Image search index size to 10B documents and helped launch several innovations in Image Search for which he got the prestigious Yahoo SuperStar Award.

Anand holds a Bachelor’s degree in Physics from Madras University and Master’s degree in Metallurgy from Indian Institute of Science.

Dr. Rakesh Barve is vice president of data science and engineering at Anumana and serves in the same role at nference, where he has been for almost three years. At nference, Dr. Barve is building the first large-scale, AI-based inference and decision-enabling pharmacological and clinical data platform to enable intelligent and effective clinical care solutions and drug development. He is leading engineering and product teams using AI, statistics and computer science techniques to synthesize scientifically sound knowledge from vast heterogenous volumes of biomedical and clinical healthcare data.

Prior to joining nference, Dr. Barve his undergraduate degree in Computer Science and Engineering from the Indian Institute of Technology in Bombay, followed by a PhD in Computer Science from Duke University.

Animesh Agarwal has 10+ years of experience in creating products and building businesses, in various areas of the lifesciences and healthcare industry. He is passionate about the democratization of healthcare, and believes that technology is vital to reducing the gaps in cost, access, and quality of outcomes. 

Prior to joining nference and Anumana, Animesh served as the Chief Product Officer of NeuTrace, Inc., an interventional electrophysiology company that was acquired by Anumana. Before that, Animesh worked for a healthcare venture capital investor with investments in pharma, biotech, diagnostics, and healthcare delivery. Animesh is a biomedical engineer with a Bachelors from Indian Institute of Technology Madras, an MS from University of Texas At Austin, and an MBA from The Wharton School.

Dr. Samir Awasthi is vice president of clinical research at Anumana and serves in the same role at nference, where he has been for more than two years. Dr. Awasthi has worked closely with Mayo Clinic, pioneering new AI-enabled algorithms to detect disease in ways never before possible. He is currently leading clinical research projects in areas including predictive analytics, external control arms, post-marketing outcomes assessments, lifecycle management and novel target identification. 

Prior to joining nference, Dr. Awasthi obtained his BS and MEng in Physics and Biomedical Engineering, respectively, from MIT, followed by an MD-PhD from the University of California, Davis, where he completed doctoral research at the NSF Center for Biophotonics Science and Technology (CBST). At CBST, he developed new approaches to imaging adult and stem cell-derived heart cells using nonlinear optical phenomena. He completed additional clinical and research training in Psychiatry at Harvard Medical School and is board-certified in Psychiatry.

Dr. Tyler Wagner is vice president of biomedical research at Anumana and serves in the same role at nference, where has been for more than three years. Dr. Wagner has worked closely with Mayo Clinic, developing new AI-enabled algorithms for innovative disease prediction. He is currently leading clinical research projects ranging from early detection of disease to real-world outcomes assessment, and is working to apply machine learning to outstanding questions in multiple therapeutic areas, including cardiology, oncology, and neuroscience.

He is currently leading clinical research projects ranging from early detection of disease to real-world outcomes assessment, and is working to apply machine learning to outstanding questions in multiple therapeutic areas, including cardiology, oncology and neuroscience.

Prior to joining nference and Anumana, Dr. Wagner obtained his PhD in the Weiss lab (MIT) and Densmore lab (BU) where he engineered both an RNA virus and mRNA into multi-functional platforms for regulated gene delivery. He continued with a post-doctorate in the Weiss lab where he explored in vivo regulatory strategies for RNA therapeutics.

Kirubel Frew is the Vice President of Business Development at Anumana & nference. 

Kirubel is interested in scaling companies bringing cutting-edge technologies and medicines to patients faster. Kirubel joined nference in 2020 from Lazard's Healthcare M&A advisory practice where he led cross-functional teams on buy-side and sell-side engagements delivering broad strategic and financial advice to the board of directors and management teams of healthcare companies globally.

Kirubel started his career as part of the founding team at SQZ Biotech, a NYSE-listed clinical-stage immuno-oncology company where he co-invented a novel approach to squeezing and consequently engineering cells. Kirubel has also held research roles as a fellow at Flagship Pioneering and at the Ragon Institute of MGH, MIT and Harvard. Kirubel holds a B.S. in Chemistry and an MBA.

Suzanne Goodman is the Vice President of Regulatory and Quality at Anumana, bringing over 25 years of experience to the team and leveraging a bachelor’s degree in biomedical engineering from Duke University.   She has supported a broad range of organizations (large and small medical device manufacturers, FDA, CROs, and consulting firms) with a wide range of medical devices and pharmaceutical development tools. She specializes in startup environments creating software-as-a-medical device (SaMD) and software-controlled electrical-mechanical devices.

Suzanne joined Anumana and nference in May 2022 with the goal of fully developing the Quality and Regulatory teams and Quality Management System to support design and development of world-class, globally-marketed medical devices.    

Chair of the Department of Cardiovascular Medicine at Mayo Clinic Advisory Board Chair

Dr. Paul A. Friedman is Chair of the Department of Cardiovascular Medicine at Mayo Clinic, Rochester, Minn. He is ABIM board certified in cardiovascular medicine and cardiac electrophysiology, and is an active participant in the MOC process. 

Previously, Dr. Friedman served as Director of the Cardiac Implantable Device Lab, Mayo Clinic. He is a trained electrical engineer, with deep experience in innovation (>40 patents issued, named Minnesota Top Inventor), and scientific research (>250 scientific original publications). He is a committed educator, serving as a director for five national and international meetings, editor of seven textbooks, and author of more than 60 book chapters. He is a frequent visiting professor and lecturer at educational meetings.

Dr. Samuel J. Asirvatham is an electrophysiologist at Mayo Clinic in Rochester, Minn., where he is also a Professor of Medicine in the Division of Cardiovascular Diseases and a Professor of Pediatrics in the Division of Pediatric Cardiology. He is a consultant in cardiac electrophysiology and Program Director for the Clinical Cardiac Electrophysiology Fellowship and Director of Strategic Collaboration for the Center for Innovation at Mayo Clinic. 

 After completing medical school at the Christian Medical College in Vellore, India, his internship was at the Columbia University Medical Center in New York City. Following residency and chief residency at the University of Wisconsin-Madison, he did his clinical cardiac and electrophysiology training at the University of Oklahoma near Oklahoma City.

 Dr. Asirvatham serves as Advisory Board Innovation Lead for Anumana.

Co-Director of Artificial Intelligence in Cardiology at Mayo Clinic

Dr. Itzhak Zachi Attia is Director of Artificial Intelligence in Cardiology at Mayo Clinic in Rochester, Minn. and an Assistant Professor of Medicine in the Mayo Clinic College of Medicine and Science.

Dr. Attia is an experienced machine learning and signal processing engineer with a demonstrated history of working in the healthcare industry, designing studies and data collection pipelines, dataset creation for studies with millions of patients and development of IP in areas of machine learning in healthcare.

Dr. Attia serves as Advisory Board Technical Lead for Anumana.

Dr. Francisco Lopez-Jimenez is the chair of the Division of Preventive Cardiology, Co-Director of Artificial Intelligence in Cardiology and Director of Research at the Dan Abraham Healthy Living Center, all at Mayo Clinic in Rochester, Minn. He is currently the co-Chair of the American College of Cardiology’s Advanced Healthcare and Analytics Work Group, whose primary goal is to promote the interest and knowledge in machine learning in cardiology.

He earned his M.Sc. degree in clinical epidemiology at the Harvard School of Public Health and a Master in Business and Administration at Augsburg University after completing his cardiovascular training at Mount Sinai Medical Center in Miami, Fla., and the Brigham and Women’s Hospital, Harvard Medical School, in Boston, Mass. His research focuses on cardiovascular disease prevention as well as clinical applications of machine learning in cardiology. He has been involved in numerous population-based initiatives for heart disease prevention in Olmsted County, Minn., and overseas and co-directs an epidemiologic study in the city of Brno, the Czech Republic.

Dr. Lopez-Jimenez serves as Advisory Board Population Screening Lead for Anumana.

Leader, Digital Innovation Laboratory at Mayo Clinic

Dr. Rickey E. Carter has collaborative research interests in the areas of cardiology, diabetes, radiology, health care delivery and translational science. He actively researches new approaches to the design and analysis of research studies from a statistical perspective. Recently, his interests are extending into digital health through the development and testing of artificial intelligence (AI) algorithms. 

Dr. Carter leads the Digital Innovation Laboratory at Mayo Clinic's campus in Jacksonville, Florida. This dry lab is a machine learning shared resource that engages in activities ranging from using electrocardiogram for the detection of cardiovascular diseases to performing work-design and unsupervised-image segmentation for high-resolution digital representations of tissue samples. The goal of Dr. Carter's lab is to help accelerate discovery and improve care by providing new tools to aid front-line health care providers.

Dr. Carter serves as Advisory Board Statistical and Study Design Lead for Anumana.

About Us

Leadership

Murali Aravamudan

David McMullin

Hutch Fishman

Anand Ramani

Rakesh Barve, PhD

Animesh Agarwal

Samir Awasthi, MD, PhD

Tyler Wagner, PhD

Kirubel Frew

Suzanne Goodman

Advisors

Paul Friedman, MD

Samuel J. Asirvatham, MD

Zachi Attia, PhD

Francisco Lopez-Jiminez, MD, MBA

Rickey Carter, PhD